Industry

Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detection of molecular residual disease (MRD). The patent, US Patent No. 11,408,033 (the “‘033 patent”), … [Read more…]

MedAvail to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

MISSISSAUGA, Ontario & PHOENIX–(BUSINESS WIRE)–MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled retail pharmacy company, today announced that the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 1:20 p.m. ET. Interested parties can access … [Read more…]

Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Showcase, taking place virtually. Management is scheduled to present on Wednesday, August 31, … [Read more…]

Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update

Hosting Call on Wednesday, August 24th at 5 pm ET TORONTO & DALLAS–(BUSINESS WIRE)–Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today announced it will report its second quarter … [Read more…]

Exscientia Business Update for Second Quarter and First Half 2022

OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of … [Read more…]

Harpak-ULMA Selected to Support Federal Pipette Tip Production Contract

Federal initiative aggressively expands domestic production of vital research tool to meet current and future capacity demands TAUNTON, Mass.–(BUSINESS WIRE)–#3Acertification–Harpak-ULMA, the industry leader in smart, connected packaging solutions, has been selected by a major medical device producer to provide automated flow wrap packaging lines for pipette tip production. The move will ensure reliable, US-based production … [Read more…]

MedWand™ Solutions, Inc. is Transforming Telemedicine with Award-Winning Device and VirtualCare Platform, Now Available

MedWand™ Solutions Receives FDA 510(k) Clearance Evaluation Kit, Mobile Clinic, & Remote Clinics Available for Health Professionals TODAY RANCHO SANTA MARGARITA, Calif. & LAS VEGAS–(BUSINESS WIRE)–MedWand Solutions, Inc. is pleased to announce that the company’s groundbreaking MedWand device and VirtualCare ecosystem is commercially available to enable clinical exams with its comprehensive care solutions. Poised to … [Read more…]

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing ZYNTEGLO will be available through a network of Qualified Treatment Centers with experience delivering novel cell and gene therapies “my … [Read more…]

bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels Management team to host conference call Thursday, August 18 at 8:00 am ET SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has approved … [Read more…]

Cross Country Healthcare to Host Investor Day on September 14, 2022, Highlighting Its Innovative Strategy

BOCA RATON, Fla.–(BUSINESS WIRE)–Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN), a market-leading tech-enabled workforce solutions platform and advisory firm, today announced that the organization will host its Investor Day event the morning of Wednesday, September 14, 2022. Those interested in attending the event in person may reach out to Josh Vogel, Vice President of … [Read more…]